<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Pediatr Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Pediatr Endocrinol</journal-id><journal-title-group><journal-title>International Journal of Pediatric Endocrinology</journal-title></journal-title-group><issn pub-type="ppub">1687-9848</issn><issn pub-type="epub">1687-9856</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25435886</article-id><article-id pub-id-type="pmc">4247194</article-id><article-id pub-id-type="publisher-id">359</article-id><article-id pub-id-type="doi">10.1186/1687-9856-2014-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Slattery</surname><given-names>Meghan</given-names></name><address><email>mslattery@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bredella</surname><given-names>Miriam A</given-names></name><address><email>mbredella@partners.org</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Stanley</surname><given-names>Takara</given-names></name><address><email>tstanley@partners.org</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Torriani</surname><given-names>Martin</given-names></name><address><email>mtorriani@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Misra</surname><given-names>Madhusmita</given-names></name><address><email>mmisra@partners.org</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, BUL 457B, Neuroendocrine Unit, 55 Fruit Street, MGH, Boston, MA 02114 USA </aff><aff id="Aff2"><label/>Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA </aff><aff id="Aff3"><label/>Pediatric Endocrine Unit, Massachusetts General Hospital for Children and Harvard Medical School, Boston, MA 02114 USA </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>2014</volume><issue>1</issue><elocation-id>22</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Slattery et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Obesity is associated with a relative deficiency of growth hormone, which is predictive of greater visceral fat and markers of cardiovascular risk. The study&#x02019;s purpose was to use recombinant human growth hormone (rhGH) as a physiologic probe to assess the effects of reversing obesity-related GH deficiency on body composition, cardiovascular risk markers, and insulin resistance.</p></sec><sec><title>Methods</title><p>22 obese girls 13&#x02013;21 years old were followed for a randomized 6-month trial of rhGH vs. placebo/no treatment. At baseline and 6-months, DXA was performed for body composition, MRI to measure visceral, subcutaneous and total adipose tissue (VAT, SAT and TAT), and fasting blood drawn for IGF-1, inflammatory cardiovascular risk markers [soluble intercellular adhesion molecule (sICAM), high sensitivity CRP], lipids and HbA1C. An oral glucose tolerance test (OGTT) was performed. Twelve girls completed the 6-month visit. Baseline and mean 6-month change were compared between the groups using the Student <italic>t</italic>-test and the relationship between variables was determined through multiple regression analysis.</p></sec><sec><title>Results</title><p>After 6-months, the rhGH group maintained IGF-1 levels, and had decreases in total cholesterol (p&#x02009;=&#x02009;0.03), sICAM-1 (p&#x02009;=&#x02009;0.04) and HbA1C (p&#x02009;=&#x02009;0.03) compared to placebo/no treatment. The rhGH group trended towards greater decreases in LDL and 2-hour OGTT glucose. Glucose tolerance did not worsen with rhGH administration.</p></sec><sec><title>Conclusions</title><p>Administering rhGH in small doses is able to stabilize IGF-1 levels in obesity. We have also shown that rhGH administration leads to an improvement in some markers of cardiovacular risk with without adversely affecting glucose tolerance.</p></sec><sec><title>Trial registration</title><p>Clinical Trial Registration Number: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01169103">NCT01169103</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adolescents</kwd><kwd>Growth hormone</kwd><kwd>Visceral fat</kwd><kwd>Body composition</kwd><kwd>Females</kwd><kwd>Inflammatory markers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Obesity, a pressing global issue, is characterized by diminished growth hormone (GH) secretion in adults [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] and adolescents [<xref ref-type="bibr" rid="CR3">3</xref>], with decreased frequency and amplitude of GH secretory bursts [<xref ref-type="bibr" rid="CR4">4</xref>]. Pathological GH deficiency is characterized by a high risk cardiovascular profile [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], and similarly, in obese individuals, relatively low GH levels are associated with higher visceral fat [<xref ref-type="bibr" rid="CR3">3</xref>], which in turn predisposes individuals to components of the metabolic syndrome [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], including hyperlipidemia [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and insulin resistance [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. While GH replacement in children with pathologic GH deficiency causes a decrease in visceral adiposity [<xref ref-type="bibr" rid="CR13">13</xref>], effects of GH administration on body composition have not been examined in an otherwise healthy adolescent obese population that is relatively GH insufficient.</p><p>Existing studies examining the effects of rh(GH) on obesity and cardiovascular risk factors have largely been performed either on adults or in children with specific chronic health conditions such as GH deficiency [<xref ref-type="bibr" rid="CR13">13</xref>] or Prader-Willi Syndrome [<xref ref-type="bibr" rid="CR14">14</xref>]. Consequently, there is a dearth of data regarding effects of GH replacement on body composition and cardiometabolic risk in otherwise healthy obese adolescents. This proof-of-concept study used rhGH as a physiologic probe to observe the effects of GH replacement on body composition. We hypothesized that rhGH administration in replacement doses to obese adolescent females would have lipolytic effects without deleterious effects on glucose tolerance.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>The study was approved by the Institutional Review Board of Partners HealthCare system. Written informed consent (for patients &#x02265;18&#x000a0;years) or parental consent with participant assent (for patients &#x0003c;18&#x000a0;years) was obtained from all.</p><sec id="Sec3"><title>Subject selection</title><p>Participants were recruited at Massachusetts General Hospital (MGH) between September 2010 and October 2012 through area pediatric and obesity clinics. Of 32 girls and young women 13&#x02013;21 years old assessed for study eligibility, 22 obese adolescents met inclusion criteria and were randomized. Inclusion criteria comprised (i) a bone age &#x02265;14&#x000a0;years, (ii) body mass index (BMI)&#x02009;&#x0003e;&#x02009;95th percentile for age (based on the 2000 Centers for Disease Control and Prevention Growth Charts) [<xref ref-type="bibr" rid="CR15">15</xref>], or &#x0003e;30&#x000a0;kg/m<sup>2</sup> if age &#x0003e;18&#x000a0;years, (iii) insulin like growth factor-1 (IGF-1) level below the median for pubertal stage or age, (iv) abdominal obesity with a waist to hip ratio (W/H) &#x0003e;0.85, and (v) stable weight (&#x0003c;5&#x000a0;kg change in weight in the prior 3&#x000a0;months). Exclusion criteria included diabetes mellitus, untreated thyroid dysfunction, chronic renal insufficiency, current or past malignancy, syndromic obesity, pregnancy, breast-feeding, and use of medications known to alter glucose metabolism or body composition (contraceptive pills, daily glucocorticoid use, metformin, sibutramine and Orlistat). Additionally, we excluded girls with new (&#x0003c;6&#x000a0;months) or unstable dosing (dosage change within 3-months) of antipsychotic medications known to cause weight gain. Baseline characteristics for a subset of study participants have been previously published [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Eleven subjects were randomized to active rhGH treatment {rhGH (+)} and 11 to rhGH negative {rhGH (-)} treatment. Sixteen subjects {10 rhGH (+) and 6 rhGH (-)} completed the 3-month visit, and 12 subjects {5 rhGH (+) and 7 rhGH (-)} finished the 6-month study period (one rhGH (-) subject missed the 3-month visit but completed other visits). No subject dropped out because of side effects. Of subjects who withdrew (n&#x02009;=&#x02009;10), one chose to begin an oral contraceptive, 3 withdrew because of personal obligations, and the remaining were considered lost to follow-up (n&#x02009;=&#x02009;6). Study participants who did or did not complete the study did not differ for baseline characteristics.</p></sec><sec id="Sec4"><title>Experimental protocol</title><p>The study was a 6-month, single-blind, randomized trial, conducted at the Clinical Research Center of MGH. The screening visit included a history and physical examination and blood sampling to ensure participants met inclusion criteria and to rule out exclusion criteria. Diabetes was ruled out via an oral glucose tolerance test (OGTT). Eligible subjects returned for the baseline visit, visits at 1 and 2&#x000a0;weeks (for dose adjustment), and at 1, 3 and 6&#x000a0;months. Subjects were randomized 1:1 to receive once daily subcutaneous rhGH or placebo injections (Somatropin, Genentech, Inc., San Francisco, CA, USA), and taught to self inject medication daily for 6-months. Due to non-availability of placebo (and inability for new placebo to be manufactured) after June 2012, subjects subsequently randomized to placebo (n&#x02009;=&#x02009;4) were instead randomized to no treatment. Dieticians and the radiologist who performed study related procedures as well as all subjects who enrolled prior to June 2012 (N&#x02009;=&#x02009;15) remained blinded to randomization status for the entirety of the study. After the placebo expiration necessitated the change in the study design, one subject randomized to rhGH (+) subject and one subject randomized to rhGH (-) treatment dropped out. The subject randomized to rhGH (-) treatment withdrew due to the initiation of an oral contraceptive while the subject randomized to rhGH (+) was lost to follow up after the 3&#x000a0;month visit.</p><p>The starting rhGH dose was 0.4&#x000a0;mg and increased at week-1 and week-2 to 0.6&#x000a0;mg and 0.8&#x000a0;mg respectively. The dosing was based on a dose of 12.5 mcg/kg/day for a 16-year-old girl (mean for bone ages 14&#x02013;18 years) weighing 67&#x000a0;kg (85th percentile for age) [<xref ref-type="bibr" rid="CR17">17</xref>]. This dosage (0.8&#x000a0;mg at week-2) is at the lower end of the 12.5&#x02013;25 mcg/kg/day dose used in studies of GH deficient adolescents transitioning from pediatric (40&#x02013;45 mcg/kg/day) to adult (2&#x02013;6 mcg/kg/day) replacement rhGH doses [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. We opted for this lower dose as we expected lower GH requirements in this population that is relatively, rather than completely, GH insufficient. The dose was adjusted as needed by 20% at the 1 and 3-month visits to achieve IGF-1 levels in the upper half of the normal range for pubertal stage. When target IGF-1 was achieved, the individualized dose was continued.</p></sec><sec id="Sec5"><title>Study procedures</title><p>Height was measured as the average of three measurements to the nearest 0.1&#x000a0;cm on a single calibrated wall-mounted stadiometer. Participants, wearing a hospital gown, were weighed to the nearest 0.1&#x000a0;kg on a single calibrated electronic scale. BMI was calculated as weight (in kg) divided by height (in meters<sup>2</sup>) and BMI standard deviation scores (SDS) determined from 2000 CDC charts [<xref ref-type="bibr" rid="CR15">15</xref>]. Waist measurements were taken with a plastic tape measure to the nearest 0.1&#x000a0;cm at the level of the iliac crest and umbilicus; the maximum hip circumference was measured. All measurements were taken at the end of expiration with the subject standing. Waist-to-hip ratio (W/H) was calculated as the iliac divided by the hip circumference measurement. An ophthalmoscope was used to rule out papilledema at study onset, and at the 3 and 6-month visits, or if any subject complained of headaches, vision changes, nausea or vomiting. Subjects had a left hand x-ray to assess bone age [<xref ref-type="bibr" rid="CR19">19</xref>]. Pubertal stage was determined according to the criteria of Tanner [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Magnetic resonance imaging (MRI) at the level of L4 was used to determine visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) at baseline and 6&#x000a0;months; total abdominal adipose tissue (TAT) was calculated as VAT&#x02009;+&#x02009;SAT [<xref ref-type="bibr" rid="CR21">21</xref>]. MRI data are available for 11 completers (due to scheduling conflicts one no-treatment subject was unable to perform the MRI component). Body composition was also obtained by dual energy x-ray absorptiometry scans (DXA) at the baseline, 3 and 6-month visits. DXA (Hologic QDR-Discovery A; Hologic Inc., Waltham, MA software version APEX 3.3) was used to assess percent body fat, total, trunk and extremity fat and total and extremity lean mass.</p><p>Subjects met with nutritionists of the Clinical Research Center at the baseline, 3 and 6-month visits for (i) basic lifestyle counseling including healthy eating habits and optimizing exercise, and (ii) assessment of prior activity using the Modified Activity Questionnaire (MAQ) [<xref ref-type="bibr" rid="CR22">22</xref>]. To avoid confounding variables, further dietary or exercise restrictions were not imposed.</p><p>Fasting blood samples were drawn for IGF-1 at each visit for rhGH dose adjustment, and a 75-g, 2-hour OGTT performed at screen, 3 and 6-months to determine whether rhGH administration had deleterious effects on glucose tolerance. Fasting blood samples were also assessed for cardiovascular risk markers [lipids, high sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1)], HbA1C, glucose and insulin levels at baseline and 6-months.</p><p>IGF-1 was analyzed by enzyme-linked immunosorbent assay (ELISA) (Immunodiagnostic systems, Scottsdale, AZ; Limit of Detection (LOD) 3.1&#x000a0;ng/mL, CV&#x02009;&#x0003c;&#x02009;7%). Fasting insulin was analyzed by immunoassay (Cobas, Roche Diagnostics, Indianapolis, IN; LOD 0.2 &#x003bc;U/mL, CV 0.8 to 4.9%), glucose via an enzymatic <italic>in vitro</italic> test (Cobas, Roche Diagnostics, Indianapolis, IN; LOD 2&#x000a0;mg/dL, intra-assay CV 1.0%), total cholesterol, LDL and HDL via a Roche direct assay (Cobas, Roche Diagnostics, Indianapolis, IN) [total cholesterol (LOD 3&#x000a0;mg/dL, CV 0.8&#x02013;1.0%), LDL (LOD 3&#x000a0;mg/dL, intra-assay CV 0.71&#x02013;1.22%) and HDL (LOD 3&#x000a0;mg/dL, intra-assay CV 0.60&#x02013;0.95%)], triglycerides via the Roche triglyceride assay (Cobas, Roche Diagnostics, Indianapolis, IN; LOD 4&#x000a0;mg/dL, intra-assay CV 0.9&#x02013;1.5%), and VLDL calculated by subtracting LDL and HDL from total cholesterol. sICAM-1 was analyzed by ELISA (RnD Systems, Minneapolis, MN; minimum detectable concentration 1&#x000a0;ng/mL, CV&#x02009;&#x0003c;&#x02009;8%), hsCRP via an immunoradiometric assay (IRMA) (LabCorp, Burlington, NC; LOD 0.3&#x000a0;mg/L, intra-assay CV&#x02009;&#x0003c;&#x02009;10%). ALT was analyzed by the Architect assay (Abbott, Abbott Park, IL; LOD 2.0 U/L, intra-assay CV&#x02009;&#x0003c;&#x02009;5.2%). Serum was stored at -80&#x000b0;C for insulin, ALT, and cardiovascular risk factors until analysis. Other samples were analyzed in real time.</p></sec><sec id="Sec6"><title>Statistical methods</title><p>JMP Software (v10: SAS Institute, Inc., Cary, NC) was used for analysis. Results are reported as means&#x02009;&#x000b1;&#x02009;SD. Baseline and mean 6-month change were compared using the Student <italic>t</italic>-test or Wilcoxon rank sum test depending on data distribution. A paired <italic>t</italic>-test was also used to compare baseline and 6&#x000a0;month values within groups. Parametric (Pearson) or nonparametric (Spearman) correlations were used as appropriate to determine associations between variables that were or were not normally distributed. Significance was defined as a two-tailed p-value of &#x0003c;0.05. Multivariate regression models were constructed to determine whether significances for changes in endpoints persisted after controlling for weight changes or baseline values of the endpoint (i.e. HbA1c).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Baseline characteristics</title><p>Baseline characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Study participants had a mean age of 16.6&#x02009;&#x000b1;&#x02009;2.4&#x000a0;years, mean weight of 100.1&#x02009;&#x000b1;&#x02009;20.5&#x000a0;kg, and a mean BMI of 38.5&#x02009;&#x000b1;&#x02009;7.5&#x000a0;kg/m<sup>2</sup>. Treatment groups did not differ for baseline characteristics except for a slightly lower HbA1C in the rhGH (-) group. There were no significant baseline differences noted between the blinded (N&#x02009;=&#x02009;15) and unblinded (N&#x02009;=&#x02009;7) groups with one exception; the W/H ratio was higher in the group who remained blinded to their treatment allocation (0.96&#x02009;&#x000b1;&#x02009;0.06 vs. 0.90&#x02009;&#x000b1;&#x02009;0.07, p&#x02009;=&#x02009;0.05). All subjects were Tanner Stage V for breast development at the baseline visit.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline characteristics of all obese adolescent girls at study entry</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>RhGH + N&#x02009;=&#x02009;11</th><th>RhGH - N&#x02009;=&#x02009;11</th><th>P</th></tr></thead><tbody><tr><td>Age (years)</td><td>16.2&#x02009;&#x000b1;&#x02009;2.6</td><td>16.9&#x02009;&#x000b1;&#x02009;2.2</td><td>0.50</td></tr><tr><td>Bone age (years)</td><td>16.9&#x02009;&#x000b1;&#x02009;1.2</td><td>17.2&#x02009;&#x000b1;&#x02009;1.3</td><td>0.56</td></tr><tr><td>Weight (kg)</td><td>104.7&#x02009;&#x000b1;&#x02009;24.8</td><td>97.4&#x02009;&#x000b1;&#x02009;15.4</td><td>0.42</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>40.4&#x02009;&#x000b1;&#x02009;8.4</td><td>36.6&#x02009;&#x000b1;&#x02009;6.4</td><td>0.25*</td></tr><tr><td>BMI SDS</td><td>2.3&#x02009;&#x000b1;&#x02009;0.4</td><td>2.1&#x02009;&#x000b1;&#x02009;0.4</td><td>0.22</td></tr><tr><td>Waist circumference (cm)</td><td>119.4&#x02009;&#x000b1;&#x02009;17.1</td><td>115.0&#x02009;&#x000b1;&#x02009;14.8</td><td>0.53</td></tr><tr><td>W/H ratio</td><td>0.95&#x02009;&#x000b1;&#x02009;0.06</td><td>0.93&#x02009;&#x000b1;&#x02009;0.08</td><td>0.62</td></tr><tr><td>SAT (cm<sup>2</sup>)</td><td>615.6&#x02009;&#x000b1;&#x02009;175.0</td><td>580.0&#x02009;&#x000b1;&#x02009;176.9 (N&#x02009;=&#x02009;9)</td><td>0.66</td></tr><tr><td>VAT (cm<sup>2</sup>)</td><td>90.6&#x02009;&#x000b1;&#x02009;35.3</td><td>87.1&#x02009;&#x000b1;&#x02009;31.8 (N&#x02009;=&#x02009;9)</td><td>0.82</td></tr><tr><td>TAT (cm<sup>2</sup>)</td><td>706.2&#x02009;&#x000b1;&#x02009;203.5</td><td>667.2&#x02009;&#x000b1;&#x02009;179.8 (N&#x02009;=&#x02009;9)</td><td>0.66</td></tr><tr><td>Thigh subcutaneous fat (cm<sup>2</sup>)</td><td>224.2&#x02009;&#x000b1;&#x02009;69.4</td><td>221.4&#x02009;&#x000b1;&#x02009;96.3</td><td>0.95</td></tr><tr><td>Lean mass (grams)</td><td>54353&#x02009;&#x000b1;&#x02009;9719</td><td>52276&#x02009;&#x000b1;&#x02009;6842</td><td>0.57</td></tr><tr><td>IGF-1 (ng/mL)</td><td>250.6&#x02009;&#x000b1;&#x02009;129.9</td><td>271.8&#x02009;&#x000b1;&#x02009;73.1</td><td>0.64</td></tr><tr><td>2 HR glucose (OGTT) (mg/dL)</td><td>107.1&#x02009;&#x000b1;&#x02009;20.5</td><td>114.0&#x02009;&#x000b1;&#x02009;18.5</td><td>0.42</td></tr><tr><td>HbA1c (%)</td><td>5.78&#x02009;&#x000b1;&#x02009;0.30</td><td>5.49&#x02009;&#x000b1;&#x02009;0.30</td><td>
<bold>0.03</bold>
</td></tr><tr><td>Insulin uU/mL</td><td>26.4&#x02009;&#x000b1;&#x02009;21.3</td><td>40.1&#x02009;&#x000b1;&#x02009;37.2</td><td>0.29*</td></tr><tr><td>Total cholesterol (mg/dL)</td><td>167.6&#x02009;&#x000b1;&#x02009;38.3</td><td>156.0&#x02009;&#x000b1;&#x02009;33.5</td><td>0.46</td></tr><tr><td>LDL (mg/dL)</td><td>103.8&#x02009;&#x000b1;&#x02009;28.8</td><td>92.6&#x02009;&#x000b1;&#x02009;30.1</td><td>0.33*</td></tr><tr><td>HDL (mg/dL)</td><td>45.1&#x02009;&#x000b1;&#x02009;9.4</td><td>43.3&#x02009;&#x000b1;&#x02009;8.5</td><td>0.64</td></tr><tr><td>VLDL (mg/dL)</td><td>18.6&#x02009;&#x000b1;&#x02009;9.4</td><td>20.1&#x02009;&#x000b1;&#x02009;8.0</td><td>0.70</td></tr><tr><td>Triglycerides (mg/dL)</td><td>93.0&#x02009;&#x000b1;&#x02009;47.0</td><td>100.6&#x02009;&#x000b1;&#x02009;39.8</td><td>0.69</td></tr><tr><td>hsCRP (mg/L)</td><td>4.47&#x02009;&#x000b1;&#x02009;2.76</td><td>3.41&#x02009;&#x000b1;&#x02009;3.29</td><td>0.25*</td></tr><tr><td>sICAM-1 (ng/mL)</td><td>268.7&#x02009;&#x000b1;&#x02009;72.5</td><td>220.9&#x02009;&#x000b1;&#x02009;56.4</td><td>0.10</td></tr></tbody></table><table-wrap-foot><p>*P value reported for log transformed values.</p><p>RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.</p><p>
<italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>BMI SDS</italic> body mass index standard deviation score, <italic>HbA1c</italic> hemoglobin A1c, <italic>HDL</italic> high density lipoprotein, <italic>hsCRP</italic> high sensitivity C-reactive protein, <italic>IGF-1</italic> insulin like growth factor-1, <italic>LDL</italic> low density lipoprotein, <italic>OGTT</italic> oral glucose tolerance test, <italic>SAT</italic> subcutaneous adipose tissue, <italic>sICAM-1</italic> soluble intercellular adhesion molecule 1, <italic>TAT, VAT</italic> total, visceral adipose tissue, <italic>VLDL</italic> very low density lipoprotein, <italic>W/H</italic> waist to hip ratio.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Six-month changes in nutritional measures</title><p>No differences were noted between rhGH(+) and rhGH(-) groups for changes in calories consumed (142.6&#x02009;&#x000b1;&#x02009;961.0 vs. 193.5&#x02009;&#x000b1;&#x02009;644.0&#x000a0;kcal, p&#x02009;=&#x02009;0.93), percentage of calories from fat (-8.09&#x02009;&#x000b1;&#x02009;12.04 vs. 0.09&#x02009;&#x000b1;&#x02009;12.95%, p&#x02009;=&#x02009;0.36), or activity levels (1.64&#x02009;&#x000b1;&#x02009;6.4 vs. 8.83&#x02009;&#x000b1;&#x02009;9.48&#x000a0;hours/week, p&#x02009;=&#x02009;0.18).</p></sec><sec id="Sec10"><title>Six-month changes in IGF-1 levels</title><p>Changes in IGF-1 trended higher in the treatment group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). At the 6-month visit, mean IGF-1 in the rhGH(+) group was non-significantly higher than in the rhGH(-) group (234&#x02009;&#x000b1;&#x02009;24.3 vs. 185.6&#x02009;&#x000b1;&#x02009;20.5&#x000a0;ng/mL, p&#x02009;=&#x02009;0.16).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Baseline, 6-month and change in body composition and biochemical parameters over 6-months for study completers</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>RhGH +</th><th/><th colspan="3">RhGH -</th><th/></tr><tr><th/><th>Baseline</th><th>6-month N&#x02009;=&#x02009;5</th><th>6-month delta</th><th>Baseline</th><th>6-month N&#x02009;=&#x02009;7</th><th>6-month delta</th><th>6&#x000a0;month delta P</th></tr></thead><tbody><tr><td>Weight (kg)</td><td align="center">99.9&#x02009;&#x000b1;&#x02009;29.5</td><td align="center">100.6&#x02009;&#x000b1;&#x02009;30.9</td><td align="center">0.7&#x02009;&#x000b1;&#x02009;4.3</td><td align="center">96.5&#x02009;&#x000b1;&#x02009;18.1</td><td align="center">100.4&#x02009;&#x000b1;&#x02009;23.1</td><td align="center">3.9&#x02009;&#x000b1;&#x02009;6.6</td><td align="center">0.81*</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td align="center">39.6&#x02009;&#x000b1;&#x02009;10.2</td><td align="center">39.8&#x02009;&#x000b1;&#x02009;10.8</td><td align="center">0.2&#x02009;&#x000b1;&#x02009;2.0</td><td align="center">36.4&#x02009;&#x000b1;&#x02009;7.3</td><td align="center">37.8&#x02009;&#x000b1;&#x02009;9.6</td><td align="center">1.4&#x02009;&#x000b1;&#x02009;2.5</td><td align="center">0.81*</td></tr><tr><td>Waist circumference (cm)</td><td align="center">115.4&#x02009;&#x000b1;&#x02009;21.7</td><td align="center">113.7&#x02009;&#x000b1;&#x02009;23.1</td><td align="center">-1.7&#x02009;&#x000b1;&#x02009;4.0</td><td align="center">112.4&#x02009;&#x000b1;&#x02009;17.0</td><td align="center">112.5&#x02009;&#x000b1;&#x02009;21.2</td><td align="center">0.1&#x02009;&#x000b1;&#x02009;6.5</td><td align="center">0.60</td></tr><tr><td>W/H ratio</td><td align="center">0.94&#x02009;&#x000b1;&#x02009;0.06</td><td align="center">0.95&#x02009;&#x000b1;&#x02009;0.06</td><td align="center">0.003&#x02009;&#x000b1;&#x02009;0.03</td><td align="center">0.91&#x02009;&#x000b1;&#x02009;0.08</td><td align="center">0.91&#x02009;&#x000b1;&#x02009;0.08</td><td align="center">-0.005&#x02009;&#x000b1;&#x02009;0.04</td><td align="center">0.72</td></tr><tr><td>SAT (cm<sup>2</sup>)</td><td align="center">578.5&#x02009;&#x000b1;&#x02009;234.8</td><td align="center">577.4&#x02009;&#x000b1;&#x02009;232.9</td><td align="center">-1.1&#x02009;&#x000b1;&#x02009;60.8</td><td align="center">570.0&#x02009;&#x000b1;&#x02009;206.4</td><td align="center">606.3&#x02009;&#x000b1;&#x02009;231.1</td><td align="center">36.3&#x02009;&#x000b1;&#x02009;51.6 (N&#x02009;=&#x02009;6)</td><td align="center">0.30</td></tr><tr><td>VAT (cm<sup>2</sup>)</td><td align="center">92.7&#x02009;&#x000b1;&#x02009;36.6</td><td align="center">93.3&#x02009;&#x000b1;&#x02009;47.3</td><td align="center">0.6&#x02009;&#x000b1;&#x02009;29.9</td><td align="center">90.4&#x02009;&#x000b1;&#x02009;39.6</td><td align="center">98.4&#x02009;&#x000b1;&#x02009;43.5</td><td align="center">8.0&#x02009;&#x000b1;&#x02009;31.9 (N&#x02009;=&#x02009;6)</td><td align="center">0.70</td></tr><tr><td>TAT (cm<sup>2</sup>)</td><td align="center">671.3&#x02009;&#x000b1;&#x02009;264.1</td><td align="center">670.7&#x02009;&#x000b1;&#x02009;278.9</td><td align="center">-0.5&#x02009;&#x000b1;&#x02009;83.3</td><td align="center">660.3&#x02009;&#x000b1;&#x02009;209.1</td><td align="center">704.6&#x02009;&#x000b1;&#x02009;234.5</td><td align="center">44.3&#x02009;&#x000b1;&#x02009;63.1 (N&#x02009;=&#x02009;6)</td><td align="center">0.34</td></tr><tr><td>Thigh subcutaneous fat (cm<sup>2</sup>)</td><td align="center">217.7&#x02009;&#x000b1;&#x02009;72.1</td><td align="center">208.7&#x02009;&#x000b1;&#x02009;73.1</td><td align="center">-9.0&#x02009;&#x000b1;&#x02009;16.0</td><td align="center">228.5&#x02009;&#x000b1;&#x02009;103.4</td><td align="center">211.2&#x02009;&#x000b1;&#x02009;72.7</td><td align="center">18.6&#x02009;&#x000b1;&#x02009;29.0 (N&#x02009;=&#x02009;6)</td><td align="center">0.08*</td></tr><tr><td>Lean mass (grams)</td><td align="center">50741.3&#x02009;&#x000b1;&#x02009;7963.2</td><td align="center">50758.1&#x02009;&#x000b1;&#x02009;8735.6</td><td align="center">17&#x02009;&#x000b1;&#x02009;2160</td><td align="center">50659.5&#x02009;&#x000b1;&#x02009;7149.8</td><td align="center">51360.7&#x02009;&#x000b1;&#x02009;7309.6</td><td align="center">701&#x02009;&#x000b1;&#x02009;2325</td><td align="center">0.62</td></tr><tr><td>IGF-1 (ng/mL)</td><td align="center">235.4&#x02009;&#x000b1;&#x02009;61.9</td><td align="center">234.0&#x02009;&#x000b1;&#x02009;48.5</td><td align="center">-1.4&#x02009;&#x000b1;&#x02009;79.4</td><td align="center">266.0&#x02009;&#x000b1;&#x02009;83.6</td><td align="center">185.9&#x02009;&#x000b1;&#x02009;58.0</td><td align="center">-80.1&#x02009;&#x000b1;&#x02009;48.8</td><td align="center">0.06</td></tr><tr><td>2 HR-glucose (OGTT) (mg/dL)</td><td align="center">119.8&#x02009;&#x000b1;&#x02009;14.8</td><td align="center">113.2&#x02009;&#x000b1;&#x02009;17.6</td><td align="center">-6.6&#x02009;&#x000b1;&#x02009;17.0</td><td align="center">112.7&#x02009;&#x000b1;&#x02009;14.2</td><td align="center">135.1&#x02009;&#x000b1;&#x02009;23.7</td><td align="center">22.4&#x02009;&#x000b1;&#x02009;28.8</td><td align="center">0.07</td></tr><tr><td>HbA1c (%)</td><td align="center">5.62&#x02009;&#x000b1;&#x02009;0.30</td><td align="center">5.58&#x02009;&#x000b1;&#x02009;0.16</td><td align="center">-0.04&#x02009;&#x000b1;&#x02009;0.17</td><td align="center">5.47&#x02009;&#x000b1;&#x02009;0.25</td><td align="center">5.61&#x02009;&#x000b1;&#x02009;0.30</td><td align="center">0.14&#x02009;&#x000b1;&#x02009;0.08</td><td align="center">
<bold>0.03</bold>
</td></tr><tr><td>Insulin uU/mL</td><td align="center">25.4&#x02009;&#x000b1;&#x02009;25.7</td><td align="center">22.6&#x02009;&#x000b1;&#x02009;17.8</td><td align="center">-2.8&#x02009;&#x000b1;&#x02009;11.7</td><td align="center">41.9&#x02009;&#x000b1;&#x02009;41.0</td><td align="center">27.1&#x02009;&#x000b1;&#x02009;22.5</td><td align="center">-14.8&#x02009;&#x000b1;&#x02009;38.3</td><td align="center">0.94*</td></tr><tr><td>Total cholesterol (mg/dL)</td><td align="center">189.2&#x02009;&#x000b1;&#x02009;42.6</td><td align="center">151.4&#x02009;&#x000b1;&#x02009;27.8</td><td align="center">-37.8&#x02009;&#x000b1;&#x02009;23.9</td><td align="center">162.1&#x02009;&#x000b1;&#x02009;39.7</td><td align="center">153.6&#x02009;&#x000b1;&#x02009;34.8</td><td align="center">-8.6&#x02009;&#x000b1;&#x02009;15.5</td><td align="center">
<bold>0.03</bold>
</td></tr><tr><td>LDL (mg/dL)</td><td align="center">121.2&#x02009;&#x000b1;&#x02009;27.7</td><td align="center">95.4&#x02009;&#x000b1;&#x02009;22.4</td><td align="center">-25.8&#x02009;&#x000b1;&#x02009;12.8</td><td align="center">98.3&#x02009;&#x000b1;&#x02009;35.8</td><td align="center">87.6&#x02009;&#x000b1;&#x02009;28.0</td><td align="center">-10.7&#x02009;&#x000b1;&#x02009;11.9</td><td align="center">0.06</td></tr><tr><td>HDL (mg/dL)</td><td align="center">48.2&#x02009;&#x000b1;&#x02009;13.4</td><td align="center">41.6&#x02009;&#x000b1;&#x02009;8.2</td><td align="center">-6.6&#x02009;&#x000b1;&#x02009;6.1</td><td align="center">44.0&#x02009;&#x000b1;&#x02009;7.4</td><td align="center">45.0&#x02009;&#x000b1;&#x02009;5.2</td><td align="center">1.0&#x02009;&#x000b1;&#x02009;5.1</td><td align="center">
<bold>0.04</bold>
</td></tr><tr><td>VLDL (mg/dL)</td><td align="center">19.8&#x02009;&#x000b1;&#x02009;11.2</td><td align="center">14.4&#x02009;&#x000b1;&#x02009;6.0</td><td align="center">-5.4&#x02009;&#x000b1;&#x02009;9.6</td><td align="center">19.9&#x02009;&#x000b1;&#x02009;7.0</td><td align="center">21.0&#x02009;&#x000b1;&#x02009;16.3</td><td align="center">1.1&#x02009;&#x000b1;&#x02009;11.7</td><td align="center">0.48*</td></tr><tr><td>Triglycerides (mg/dL)</td><td align="center">99.4&#x02009;&#x000b1;&#x02009;55.7</td><td align="center">71.6&#x02009;&#x000b1;&#x02009;29.5</td><td align="center">-27.8&#x02009;&#x000b1;&#x02009;46.8</td><td align="center">99.1&#x02009;&#x000b1;&#x02009;35.5</td><td align="center">105.3&#x02009;&#x000b1;&#x02009;24.9</td><td align="center">6.1&#x02009;&#x000b1;&#x02009;58.4</td><td align="center">0.57*</td></tr><tr><td>hsCRP (mg/L)</td><td align="center">3.5&#x02009;&#x000b1;&#x02009;2.1</td><td align="center">2.69&#x02009;&#x000b1;&#x02009;1.8</td><td align="center">-0.77&#x02009;&#x000b1;&#x02009;2.36</td><td align="center">4.4&#x02009;&#x000b1;&#x02009;3.8</td><td align="center">4.27&#x02009;&#x000b1;&#x02009;4.6</td><td align="center">-0.09&#x02009;&#x000b1;&#x02009;1.79</td><td align="center">0.58</td></tr><tr><td>sICAM-1 (ng/mL)</td><td align="center">226.4&#x02009;&#x000b1;&#x02009;79.3</td><td align="center">204.2&#x02009;&#x000b1;&#x02009;74.5</td><td align="center">-22.2&#x02009;&#x000b1;&#x02009;30.3</td><td align="center">241.1&#x02009;&#x000b1;&#x02009;48.1</td><td align="center">262.2&#x02009;&#x000b1;&#x02009;74.8</td><td align="center">21.1&#x02009;&#x000b1;&#x02009;33.3</td><td align="center">
<bold>0.04</bold>
</td></tr></tbody></table><table-wrap-foot><p>*Wilcoxon rank sum test.</p><p>HbA1c, Total Cholesterol, HDL and sICAM were lower after 6&#x000a0;months of rhGH&#x02009;+&#x02009;treatment.</p><p>RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.</p><p>Baseline: Mean Baseline values only for study completers.</p><p>6-month: Mean 6-month values for study completers.</p><p>6-month delta: Change over 6-months from Mean Baseline to Mean 6-month values.</p><p>
<italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>BMI SDS</italic> body mass index standard deviation score, <italic>HbA1c</italic> hemoglobin A1c, <italic>HDL</italic> high density lipoprotein, <italic>hsCRP</italic> high sensitivity C-reactive protein, <italic>IGF-1</italic> insulin like growth factor-1, <italic>LDL</italic> low density lipoprotein, <italic>OGTT</italic> oral glucose tolerance test, <italic>SAT</italic> subcutaneous adipose tissue, <italic>sICAM-1</italic> soluble intercellular adhesion molecule 1, <italic>TAT, VAT</italic> total, visceral adipose tissue, <italic>VLDL</italic> very low density lipoprotein, <italic>W/H</italic> waist to hip ratio.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Six-month changes in body composition</title><p>Body composition changes across treatment groups are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Although changes in waist circumference and W/H ratio did not differ across groups over the study duration, the increase in IGF-1 between 3&#x02013;6 months correlated with the decrease in W/H ratio over 6-months (r&#x02009;=&#x02009;-0.74 p&#x02009;=&#x02009;0.009). A similar finding was also seen in the negative correlation between change in IGF-1 over 3-months and change in body fat percentage over 3-months (r&#x02009;=&#x02009;-0.65 p&#x02009;=&#x02009;0.009) (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). SAT and TAT decreased non-significantly in the treatment group compared to an increase in the control group, and VAT showed a negligible increase compared to the control group.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Correlation between 3-month changes in IGF-1 and body fat percentage within the rhGH treated group.</bold> 3-month increase in IGF-1 was associated with the 3-month decrease in % body fat.</p></caption><graphic xlink:href="13633_2014_359_Fig1_HTML" id="d30e1681"/></fig></p></sec><sec id="Sec12"><title>Six-month changes in cardiovascular risk markers</title><sec id="Sec13"><title>Lipid levels</title><p>At 6-months, subjects in the active group had significant reductions in total cholesterol compared with controls (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), and trended to have greater reductions in LDL. The treatment group also had a greater decrease in HDL compared with controls. Six-month changes in IGF-1 correlated negatively with changes in total cholesterol (r&#x02009;=&#x02009;-0.60, p&#x02009;=&#x02009;0.04) (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), VLDL (Spearman rho&#x02009;=&#x02009;-0.58, p&#x02009;=&#x02009;0.05), and triglycerides (Spearman rho&#x02009;=&#x02009;-0.67, p&#x02009;=&#x02009;0.02) but not HDL (r&#x02009;=&#x02009;-0.37, p&#x02009;=&#x02009;0.24).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Correlation of 6-month change in IGF-1 with 6-month change in total cholesterol for all subjects.</bold> 6-month increase in IGF-1 was associated with the 6-month decrease in total cholesterol.</p></caption><graphic xlink:href="13633_2014_359_Fig2_HTML" id="d30e1707"/></fig></p></sec><sec id="Sec14"><title>Markers of inflammation</title><p>Subjects in the treatment group had a significant decrease in sICAM-1 (a marker of inflammation) compared to an increase in controls (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Mean changes in hsCRP did not differ across groups. Additionally, there was a trend for GH to decrease ALT, a marker of liver inflammation, (-5&#x02009;&#x000b1;&#x02009;5 vs. 3&#x02009;&#x000b1;&#x02009;11 U/L, p&#x02009;=&#x02009;0.18 for a 2-tailed test and 0.0478 for a one-tailed test).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Change in soluble intercellular adhesion molecule-1 (sICAM) levels in obese adolescent females.</bold> Change in sICAM levels in obese adolescent females after 6&#x000a0;months of recombinant human growth hormone therapy (rhGH +) (black bar) or placebo/no treatment (rhGH -) (gray bar).</p></caption><graphic xlink:href="13633_2014_359_Fig3_HTML" id="d30e1730"/></fig></p></sec></sec><sec id="Sec15"><title>Six-month changes in glycemic status</title><p>At 6-months, subjects in the active group had significant reductions in HbA1c compared to controls (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). This reduction trended to remain significant after controlling for baseline HbA1C (p&#x02009;=&#x02009;0.06). Subjects in the active group also trended to have greater reductions in 2-hour glucose levels on the OGTT (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). No difference was noted between the groups for 6-month changes in insulin levels. Thus, we did not see the anticipated deleterious effects of rhGH on glucose tolerance.</p></sec><sec id="Sec16"><title>Adverse events over the 6-month study duration</title><p>Adverse events are presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There were no serious adverse events related to study participation. rhGH was well tolerated and no subject required a dose reduction. No subject who complained of headaches, nausea or vomiting had a history or physical exam findings suggestive of pseudotumor cerebri.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Adverse events in treated obese girls (rhGH+) and untreated obese girls (rhGH -)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Event type</th><th rowspan="2">Total number of adverse events</th><th colspan="2">Adverse events</th></tr><tr><th>RhGH&#x02009;+&#x02009;(N)</th><th>RhGH - (N)</th></tr></thead><tbody><tr><td>
<bold>Serious adverse events</bold>
</td><td>-</td><td>-</td><td>-</td></tr><tr><td>
<bold>Non-serious adverse events</bold>
</td><td/><td/><td/></tr><tr><td>
<italic>Hyperglycemia related events</italic>
</td><td/><td/><td/></tr><tr><td>IGT at 3 or 6-month (OGTT)</td><td>6</td><td>2</td><td>4</td></tr><tr><td>Polyuria/Polydipsia</td><td>4</td><td>3</td><td>1</td></tr><tr><td>HbA1c&#x02009;&#x0003e;&#x02009;6.4%</td><td>1</td><td>1</td><td>-</td></tr><tr><td>
<italic>Symptoms that may relate to raised ICP</italic>
</td><td/><td/><td/></tr><tr><td>Headache</td><td>7</td><td>4</td><td>3</td></tr><tr><td>Nausea with vomiting</td><td>1</td><td>1</td><td>-</td></tr><tr><td>Nausea without vomiting</td><td>3</td><td>3</td><td>-</td></tr><tr><td>Dizziness without headache</td><td>1</td><td>-</td><td>1</td></tr><tr><td>Blurry vision</td><td>1</td><td>1</td><td>-</td></tr><tr><td>
<italic>Arthralgias/Fluid retention related events</italic>
</td><td/><td/><td/></tr><tr><td>Arthralgia</td><td>2</td><td>2</td><td>-</td></tr><tr><td>Back pain</td><td>5</td><td>4</td><td>1</td></tr><tr><td>Myalgia</td><td>1</td><td>1</td><td>-</td></tr><tr><td>Edema</td><td>-</td><td>-</td><td>-</td></tr><tr><td>
<italic>Menstrual cycle related events</italic>
</td><td/><td/><td/></tr><tr><td>Change in menstrual Flow</td><td>5</td><td>3</td><td>2</td></tr><tr><td>
<italic>Injection related events</italic>
</td><td/><td/><td/></tr><tr><td>Bruising/Irritation at injection site</td><td>4</td><td>2</td><td>2</td></tr><tr><td>Bruising/Irritation at blood sampling site</td><td>1</td><td>1</td><td>-</td></tr><tr><td>
<italic>Others</italic>
</td><td/><td/><td/></tr><tr><td>Hypertension</td><td>1</td><td>-</td><td>1</td></tr><tr><td>Lightheadedness</td><td>-</td><td>-</td><td>-</td></tr><tr><td>ED visit for wheezing with URI</td><td>1</td><td>-</td><td>1</td></tr><tr><td>Abdominal pain</td><td>2</td><td>2</td><td>-</td></tr><tr><td>Upper respiratory Infection</td><td>1</td><td>1</td><td>-</td></tr><tr><td>Nasal congestion (with URI)</td><td>1</td><td>1</td><td>-</td></tr><tr><td>Fatigue</td><td>2</td><td>-</td><td>2</td></tr><tr><td>Eczema</td><td>1</td><td>-</td><td>1</td></tr></tbody></table><table-wrap-foot><p>RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.</p><p>
<italic>Abbreviations</italic>: <italic>ED</italic> emergency department, <italic>ICP</italic> intracranial pressure, <italic>IGT</italic> impaired glucose tolerance, <italic>OGTT</italic> oral glucose tolerance test, <italic>URI</italic> upper respiratory infection.</p><p>There were no significant differences across the two groups for the various adverse events.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p>We have shown that administering rhGH to female adolescents in physiologic doses is able to stabilize IGF-1 in obesity, a state characterized by relative GH insufficiency, without adversely affecting glucose tolerance. We also confirmed the lipolytic effects of endogenous rhGH, administered for the first time to otherwise healthy obese adolescent females, resulting in a decrease in total cholesterol; additionally, we saw a reduction in sICAM-1 as opposed to an increase in sICAM-1 levels in the non-intervention group. Our group has previously reported a relative state of GH insufficiency in obese adolescent girls compared with controls, and that lower GH levels strongly predict higher visceral fat, an important determinant of insulin resistance and hyperlipidemia [<xref ref-type="bibr" rid="CR3">3</xref>]. Although GH replacement causes a decrease in visceral adiposity in GH deficient children [<xref ref-type="bibr" rid="CR13">13</xref>], effects of GH administration on body composition and cardiometabolic risk have not been previously examined in a healthy adolescent obese population.</p><p>Despite small increases in IGF-1, the dose of rhGH used in our study achieved significant reductions in total cholesterol and sICAM-1. It is thus possible that observed changes represent direct lipolytic effects of GH and direct effects of GH on inflammatory markers, rather than IGF-1 mediated effects. However, we did observe significant inverse associations between 6-month changes in IGF-1 levels and 6-month changes in total cholesterol, triglycerides, and VLDL. Although we observed a decrease in HDL levels in the active arm, no correlation was found between changes in IGF-1 levels and changes in HDL over the 6-month study period.</p><p>Of note, by the end of puberty, the increase in insulin resistance that is characteristic of puberty resolves, and returns to prepubertal levels [<xref ref-type="bibr" rid="CR23">23</xref>]. All subjects in our study were fully pubertal at the start of the study, thus any puberty related variations in insulin resistance parameters were minimized. We speculate that the decrease in sICAM levels in the active arm compared with the increase in the non-treatment arm may represent reduced inflammation in the active arm, compared to a persistent (and potentially worsening) pro-inflammatory state in the non-treatment arm. This may account for the maintenance of HbA1C levels in the intervention group, as opposed to the increase in HbA1C observed over 6&#x000a0;months in the non-intervention group. Given that rhGH studies in adults have found that even at low doses, GH treatment corresponds with elevated glucose and insulin levels [<xref ref-type="bibr" rid="CR5">5</xref>], adolescence may potentially offer a time period when rhGH replacement (in doses used in this study) will not worsen glucose tolerance.</p><p>Given the known inverse associations of GH levels with VAT and hsCRP in obesity, [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] we expected to see a reduction in VAT content and in hsCRP levels following rhGH administration. However, contrary to our expectations, neither of these parameters decreased, and it is possible that higher doses of rhGH than achieved in this study are necessary to observe such an effect. Following rhGH administration, although the mean IGF-1 level attained in the active arm was higher than in the control arm, this was not statistically significant, and mean levels remained in the lower half of the normal range despite dose titration. Thus, a state of relative GH insufficiency persisted. It is unclear why IGF-1 decreased in the control group. Although variation within the IGF-1 range is an expected finding, it is also possible that the non-significant weight gain in the control group over 6&#x000a0;months contributed to a decrease in GH, and therefore, IGF-1 secretion [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>We did observe inverse associations of changes in IGF-1 with changes in the waist/hip ratio, considered to be an excellent surrogate for VAT, which also suggests that a higher dosage of rhGH may have caused improvements in body composition and biochemical parameters overall. The fact that glucose tolerance did not deteriorate in the active arm may also be attributable to the low dosage of rhGH used in the active arm [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Further studies are necessary based on data from this proof-of-concept study to determine the most appropriate dose of rhGH to improve body composition and cardiometabolic risk markers in obese adolescent girls without significantly worsening insulin resistance.</p><p>Limitations of this study include the small sample size and relatively high drop-out rate (common in studies with obese subjects) [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. However, a significant strength was that we observed changes in lipids and an inflammatory marker despite the small sample size and low GH dose. Many previous studies examining the relationship between IGF-1 and body composition limited their findings to BMI [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and previous prospective rhGH treatment studies focused on obese adults [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The remaining studies that either prospectively or retrospectively analyzed the effects of rhGH on body composition in the pediatric population involved children with Prader-Willi syndrome or GH deficiency [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. This current study is the first to examine the effects of rhGH on otherwise healthy obese adolescents.</p></sec><sec id="Sec18" sec-type="conclusions"><title>Conclusions</title><p>In conclusion, we have demonstrated that low rhGH doses are easily tolerated with minimal side effects and are able to stabilize IGF-1 levels in obese adolescent girls. Our study confirms the lipolytic effects of growth hormone and suggests that rhGH replacement in viscerally obese adolescent females reduces total cholesterol and sICAM without adversely affecting glycemic status. Further studies are necessary to confirm these findings, and to also better understand the potential clinical role of rhGH as a treatment for obese adolescent girls.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>CV</term><def><p>Coefficient of variation</p></def></def-item><def-item><term>DXA</term><def><p>Dual energy x-ray absorptiometry scan</p></def></def-item><def-item><term>ELISA</term><def><p>Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>FAI</term><def><p>Free androgen index</p></def></def-item><def-item><term>GH</term><def><p>Growth hormone</p></def></def-item><def-item><term>HbA1c</term><def><p>Hemoglobin A1c</p></def></def-item><def-item><term>HDL</term><def><p>High density lipoprotein</p></def></def-item><def-item><term>HOMA-IR</term><def><p>Homeostasis model assessment of insulin resistance</p></def></def-item><def-item><term>hs-CRP</term><def><p>High-sensitivity C-reactive protein</p></def></def-item><def-item><term>IGF-1</term><def><p>Insulin-like growth factor 1</p></def></def-item><def-item><term>IRMA</term><def><p>Immunoradiometric assay</p></def></def-item><def-item><term>LDL</term><def><p>Low density lipoprotein</p></def></def-item><def-item><term>LOD</term><def><p>Limit of detection</p></def></def-item><def-item><term>MAQ</term><def><p>Modified activity questionnaire</p></def></def-item><def-item><term>MGH</term><def><p>Massachusetts General Hospital</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>OGTT</term><def><p>Oral glucose tolerance test</p></def></def-item><def-item><term>(rh)GH</term><def><p>Recombinant human growth hormone</p></def></def-item><def-item><term>SAT</term><def><p>Subcutaneous abdominal adipose tissue</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SDS</term><def><p>Standard deviation score</p></def></def-item><def-item><term>SHBG</term><def><p>Sex hormone binding globulin</p></def></def-item><def-item><term>sICAM-1</term><def><p>Soluble intercellular adhesion molecule-1</p></def></def-item><def-item><term>TAT/VAT</term><def><p>Total/visceral abdominal adipose tissue</p></def></def-item><def-item><term>VLDL</term><def><p>Very low density lipoprotein</p></def></def-item><def-item><term>W/H</term><def><p>Waist to hip ratio.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors state that no competing financial interests exist. This study was funded by an investigator initiated grant (L4716N) from Genentech, San Francisco, CA (with no influence on data collection/analysis). Dr. Misra received support from NIH grants UL1 RR025758 and K24 HD071843-01A1.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MM conceived the study; MB, MS and MM carried out study related procedures and performed data collection; MS, MB, MT, TS, and MM analyzed and interpreted data; MS performed the literature search; MS, MB, TS, and MM wrote the manuscript and generated figures; MM had primary responsibility for final content. All authors were involved in manuscript preparation and approved the submitted version.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the nursing and bionutrition staff of the MGH Clinical Research Center for their patient care. We also thank the Harvard Clinical and Translational Science Center for the performance of the assays. This study is registered with clinicaltrials.gov, no.: NCT01169103.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scacchi</surname><given-names>M</given-names></name><name><surname>Pincelli</surname><given-names>AI</given-names></name><name><surname>Cavagnini</surname><given-names>F</given-names></name></person-group><article-title>Growth hormone in obesity</article-title><source>Int J Obes Relat Metab Disord</source><year>1999</year><volume>23</volume><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0800807</pub-id><pub-id pub-id-type="pmid">10193871</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>C</given-names></name><name><surname>Brandberg</surname><given-names>J</given-names></name><name><surname>Lonn</surname><given-names>L</given-names></name><name><surname>Andersson</surname><given-names>B</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name><name><surname>Johannsson</surname><given-names>G</given-names></name></person-group><article-title>Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>1466</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-1657</pub-id><pub-id pub-id-type="pmid">15598680</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>M</given-names></name><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Tsai</surname><given-names>P</given-names></name><name><surname>Mendes</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>KK</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name></person-group><article-title>Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls</article-title><source>Am J Physiol Endocrinol Metab</source><year>2008</year><volume>295</volume><fpage>E385</fpage><lpage>E392</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00052.2008</pub-id><pub-id pub-id-type="pmid">18544645</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitschmann-Andermahr</surname><given-names>I</given-names></name><name><surname>Suarez</surname><given-names>P</given-names></name><name><surname>Jennings</surname><given-names>R</given-names></name><name><surname>Evers</surname><given-names>N</given-names></name><name><surname>Brabant</surname><given-names>G</given-names></name></person-group><article-title>GH/IGF-I regulation in obesity&#x02013;mechanisms and practical consequences in children and adults</article-title><source>Horm Res Paediatr</source><year>2010</year><volume>73</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1159/000284355</pub-id><pub-id pub-id-type="pmid">20197666</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maison</surname><given-names>P</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name><name><surname>Nicoue-Beglah</surname><given-names>M</given-names></name><name><surname>Haddad</surname><given-names>N</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Chanson</surname><given-names>P</given-names></name><collab>Metaanalysis of Blinded RP-CT</collab></person-group><article-title>Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>2192</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-030840</pub-id><pub-id pub-id-type="pmid">15126541</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>T</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name></person-group><article-title>Premature mortality due to cardiovascular disease in hypopituitarism</article-title><source>Lancet</source><year>1990</year><volume>336</volume><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(90)91812-O</pub-id><pub-id pub-id-type="pmid">1973979</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>AS</given-names></name><name><surname>Van&#x02019;t Hoff</surname><given-names>W</given-names></name><name><surname>Jones</surname><given-names>PJ</given-names></name><name><surname>Clayton</surname><given-names>RN</given-names></name></person-group><article-title>The effect of hypopituitarism on life expectancy</article-title><source>J Clin Endocrinol Metab</source><year>1996</year><volume>81</volume><fpage>1169</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">8772595</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KK</given-names></name><name><surname>Biller</surname><given-names>BM</given-names></name><name><surname>Lipman</surname><given-names>JG</given-names></name><name><surname>Bradwin</surname><given-names>G</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name></person-group><article-title>Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0894</pub-id><pub-id pub-id-type="pmid">15572428</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demerath</surname><given-names>EW</given-names></name><name><surname>Reed</surname><given-names>D</given-names></name><name><surname>Rogers</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Choh</surname><given-names>AC</given-names></name><name><surname>Couch</surname><given-names>W</given-names></name><name><surname>Czerwinski</surname><given-names>SA</given-names></name><name><surname>Chumlea</surname><given-names>WC</given-names></name><name><surname>Siervogel</surname><given-names>RM</given-names></name><name><surname>Towne</surname><given-names>B</given-names></name></person-group><article-title>Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">18996861</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syme</surname><given-names>C</given-names></name><name><surname>Abrahamowicz</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>GT</given-names></name><name><surname>Perron</surname><given-names>M</given-names></name><name><surname>Pitiot</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Richer</surname><given-names>L</given-names></name><name><surname>Totman</surname><given-names>J</given-names></name><name><surname>Veillette</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gaudet</surname><given-names>D</given-names></name><name><surname>Paus</surname><given-names>T</given-names></name><name><surname>Pausova</surname><given-names>Z</given-names></name></person-group><article-title>Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms</article-title><source>Arch Pediatr Adolesc Med</source><year>2008</year><volume>162</volume><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1001/archpedi.162.5.453</pub-id><pub-id pub-id-type="pmid">18458192</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>S</given-names></name><name><surname>Gutin</surname><given-names>B</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name><name><surname>Allison</surname><given-names>J</given-names></name><name><surname>Karp</surname><given-names>W</given-names></name><name><surname>Le</surname><given-names>NA</given-names></name></person-group><article-title>Visceral adipose tissue and cardiovascular risk factors in obese children</article-title><source>J Pediatr</source><year>1998</year><volume>133</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(98)70175-1</pub-id><pub-id pub-id-type="pmid">9672508</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Dufour</surname><given-names>S</given-names></name><name><surname>Taksali</surname><given-names>SE</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name><name><surname>Petersen</surname><given-names>KF</given-names></name><name><surname>Bonadonna</surname><given-names>RC</given-names></name><name><surname>Boselli</surname><given-names>L</given-names></name><name><surname>Barbetta</surname><given-names>G</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Rife</surname><given-names>F</given-names></name><name><surname>Savoye</surname><given-names>M</given-names></name><name><surname>Dziura</surname><given-names>J</given-names></name><name><surname>Sherwin</surname><given-names>R</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Caprio</surname><given-names>S</given-names></name></person-group><article-title>Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>951</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14364-4</pub-id><pub-id pub-id-type="pmid">14511928</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roemmich</surname><given-names>JN</given-names></name><name><surname>Huerta</surname><given-names>MG</given-names></name><name><surname>Sundaresan</surname><given-names>SM</given-names></name><name><surname>Rogol</surname><given-names>AD</given-names></name></person-group><article-title>Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy</article-title><source>Metabolism</source><year>2001</year><volume>50</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1053/meta.2001.22510</pub-id><pub-id pub-id-type="pmid">11319714</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrel</surname><given-names>AL</given-names></name><name><surname>Myers</surname><given-names>SE</given-names></name><name><surname>Whitman</surname><given-names>BY</given-names></name><name><surname>Allen</surname><given-names>DB</given-names></name></person-group><article-title>Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>1581</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1210/jcem.87.4.8414</pub-id><pub-id pub-id-type="pmid">11932286</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuczmarski</surname><given-names>RJ</given-names></name><name><surname>Ogden</surname><given-names>CL</given-names></name><name><surname>Grummer-Strawn</surname><given-names>LM</given-names></name><name><surname>Flegal</surname><given-names>KM</given-names></name><name><surname>Guo</surname><given-names>SS</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Curtin</surname><given-names>LR</given-names></name><name><surname>Roche</surname><given-names>AF</given-names></name><name><surname>Johnson</surname><given-names>CL</given-names></name></person-group><article-title>CDC growth charts: United States</article-title><source>Adv Data</source><year>2000</year><volume>314</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">11183293</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slattery</surname><given-names>MJ</given-names></name><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Thakur</surname><given-names>H</given-names></name><name><surname>Torriani</surname><given-names>M</given-names></name><name><surname>Misra</surname><given-names>M</given-names></name></person-group><article-title>Insulin resistance and impaired mitochondrial function in obese adolescent girls</article-title><source>Metab Syndr Relat Disord</source><year>2014</year><volume>12</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1089/met.2013.0100</pub-id><pub-id pub-id-type="pmid">24251951</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attanasio</surname><given-names>AF</given-names></name><name><surname>Shavrikova</surname><given-names>E</given-names></name><name><surname>Blum</surname><given-names>WF</given-names></name><name><surname>Cromer</surname><given-names>M</given-names></name><name><surname>Child</surname><given-names>CJ</given-names></name><name><surname>Paskova</surname><given-names>M</given-names></name><name><surname>Lebl</surname><given-names>J</given-names></name><name><surname>Chipman</surname><given-names>JJ</given-names></name><name><surname>Shalet</surname><given-names>SM</given-names></name></person-group><article-title>Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>4857</fpage><lpage>4862</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0551</pub-id><pub-id pub-id-type="pmid">15472176</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauras</surname><given-names>N</given-names></name><name><surname>Pescovitz</surname><given-names>OH</given-names></name><name><surname>Allada</surname><given-names>V</given-names></name><name><surname>Messig</surname><given-names>M</given-names></name><name><surname>Wajnrajch</surname><given-names>MP</given-names></name><name><surname>Lippe</surname><given-names>B</given-names></name></person-group><article-title>Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>3946</fpage><lpage>3955</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-0208</pub-id><pub-id pub-id-type="pmid">15855257</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greulich</surname><given-names>WW</given-names></name><name><surname>Pyle</surname><given-names>SI</given-names></name></person-group><source>Radiographic Atlas of Skeletal Development of the Hand and Wrist</source><year>1959</year><edition>2</edition><publisher-loc>Stanford, Calif</publisher-loc><publisher-name>Stanford University Press</publisher-name></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>JM</given-names></name></person-group><source>Growth at Adolescence</source><year>1962</year><edition>2</edition><publisher-loc>Springfield, Ill</publisher-loc><publisher-name>Thomas</publisher-name></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Fazeli</surname><given-names>PK</given-names></name><name><surname>Miller</surname><given-names>KK</given-names></name><name><surname>Misra</surname><given-names>M</given-names></name><name><surname>Torriani</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>BJ</given-names></name><name><surname>Ghomi</surname><given-names>RH</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name></person-group><article-title>Increased bone marrow fat in anorexia nervosa</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>2129</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-2532</pub-id><pub-id pub-id-type="pmid">19318450</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaron</surname><given-names>DJ</given-names></name><name><surname>Kriska</surname><given-names>AM</given-names></name><name><surname>Dearwater</surname><given-names>SR</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Metz</surname><given-names>KF</given-names></name><name><surname>LaPorte</surname><given-names>RE</given-names></name></person-group><article-title>Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents</article-title><source>Am J Epidemiol</source><year>1995</year><volume>142</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">7598119</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Steinberger</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>CP</given-names></name><name><surname>Prineas</surname><given-names>R</given-names></name><name><surname>Luepker</surname><given-names>R</given-names></name><name><surname>Sinaiko</surname><given-names>AR</given-names></name></person-group><article-title>Insulin resistance during puberty: results from clamp studies in 357 children</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>2039</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.2337/diabetes.48.10.2039</pub-id><pub-id pub-id-type="pmid">10512371</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Brick</surname><given-names>DJ</given-names></name><name><surname>Gerweck</surname><given-names>AV</given-names></name><name><surname>Harrington</surname><given-names>LM</given-names></name><name><surname>Torriani</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>BJ</given-names></name><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Breggia</surname><given-names>A</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Hemphill</surname><given-names>LC</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Utz</surname><given-names>AL</given-names></name><name><surname>Miller</surname><given-names>KK</given-names></name></person-group><article-title>Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial</article-title><source>Eur J Endocrinol</source><year>2012</year><volume>166</volume><fpage>601</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1530/EJE-11-1068</pub-id><pub-id pub-id-type="pmid">22275471</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Gerweck</surname><given-names>AV</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Landa</surname><given-names>MG</given-names></name><name><surname>Torriani</surname><given-names>M</given-names></name><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Hemphill</surname><given-names>LC</given-names></name><name><surname>Miller</surname><given-names>KK</given-names></name></person-group><article-title>Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><fpage>3864</fpage><lpage>3872</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2063</pub-id><pub-id pub-id-type="pmid">23824419</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>PV</given-names></name><name><surname>Christ</surname><given-names>ER</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name><name><surname>Carlsson</surname><given-names>L</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Clemmons</surname><given-names>D</given-names></name><name><surname>Hintz</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Laron</surname><given-names>Z</given-names></name><name><surname>Sizonenko</surname><given-names>P</given-names></name><name><surname>S&#x000f6;nksen</surname><given-names>PH</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Thorne</surname><given-names>M</given-names></name></person-group><article-title>Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>382</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1210/jcem.83.2.4594</pub-id><pub-id pub-id-type="pmid">9467546</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>MC</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Raether</surname><given-names>B</given-names></name><name><surname>Weissman</surname><given-names>NJ</given-names></name><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Shanahan</surname><given-names>WR</given-names></name><name><surname>Anderson</surname><given-names>CM</given-names></name></person-group><article-title>A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>3067</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-1256</pub-id><pub-id pub-id-type="pmid">21795446</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanoine</surname><given-names>JP</given-names></name><name><surname>Hampl</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Boldrin</surname><given-names>M</given-names></name><name><surname>Hauptman</surname><given-names>J</given-names></name></person-group><article-title>Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>2873</fpage><lpage>2883</lpage><pub-id pub-id-type="doi">10.1001/jama.293.23.2873</pub-id><pub-id pub-id-type="pmid">15956632</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>GD</given-names></name><name><surname>Wyatt</surname><given-names>HR</given-names></name><name><surname>Hill</surname><given-names>JO</given-names></name><name><surname>McGuckin</surname><given-names>BG</given-names></name><name><surname>Brill</surname><given-names>C</given-names></name><name><surname>Mohammed</surname><given-names>BS</given-names></name><name><surname>Szapary</surname><given-names>PO</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Edman</surname><given-names>JS</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name></person-group><article-title>A randomized trial of a low-carbohydrate diet for obesity</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>2082</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa022207</pub-id><pub-id pub-id-type="pmid">12761365</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gram</surname><given-names>IT</given-names></name><name><surname>Norat</surname><given-names>T</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Dossus</surname><given-names>L</given-names></name><name><surname>Lukanova</surname><given-names>A</given-names></name><name><surname>T&#x000e9;hard</surname><given-names>B</given-names></name><name><surname>Clavel-Chapelon</surname><given-names>F</given-names></name><name><surname>van Gils</surname><given-names>CH</given-names></name><name><surname>van Noord</surname><given-names>PA</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Nagel</surname><given-names>G</given-names></name><name><surname>Linseisen</surname><given-names>J</given-names></name><name><surname>Lahmann</surname><given-names>PH</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Sacerdote</surname><given-names>C</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Sieri</surname><given-names>S</given-names></name><name><surname>Dorronsoro</surname><given-names>M</given-names></name><name><surname>Quir&#x000f3;s</surname><given-names>JR</given-names></name><name><surname>Navarro</surname><given-names>CA</given-names></name><name><surname>Barricarte</surname><given-names>A</given-names></name><name><surname>Tormo</surname><given-names>MJ</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>CA</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Paaske Johnsen</surname><given-names>S</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Ti&#x000f8;nneland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women</article-title><source>Int J Obes (Lond)</source><year>2006</year><volume>30</volume><fpage>1623</fpage><lpage>1631</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0803324</pub-id><pub-id pub-id-type="pmid">16552400</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>KD</given-names></name><name><surname>Goran</surname><given-names>MI</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name></person-group><article-title>Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><fpage>2298</fpage><lpage>2302</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0344</pub-id><pub-id pub-id-type="pmid">17119061</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillion</surname><given-names>M</given-names></name><name><surname>Deal</surname><given-names>C</given-names></name><name><surname>Van Vliet</surname><given-names>G</given-names></name></person-group><article-title>Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome</article-title><source>J Pediatr</source><year>2009</year><volume>154</volume><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2008.07.058</pub-id><pub-id pub-id-type="pmid">18814886</pub-id></element-citation></ref></ref-list></back></article>